Samsung Pharm Applies to MFDS for Approval of Protocol Amendment for GV1001 Phase 2b/3 Trial in Progressive Supranuclear Palsy
Samsung Pharm announced on the 28th that it has submitted an application for approval of a protocol amendment for its domestic phase 2b/3 clinical trial of GV1001, a treatment candidate for progressive supranuclear palsy, to the Ministry of Food and Drug Safety. The trial targets patients with prog

Samsung Pharm announced on the 28th that it has submitted an application for approval of a protocol amendment for its domestic phase 2b/3 clinical trial of GV1001, a treatment candidate for progressive supranuclear palsy, to the Ministry of Food and Drug Safety.
The trial targets patients with progressive supranuclear palsy Richardson syndrome (PSP-RS). It aims to identify the optimal dose of GV1001 (active ingredient tertomotide hydrochloride) and confirm its efficacy in improving disease severity as well as its safety.
Multicenter, Double-Blind Trial Design Enrolling 360 Patients
The trial will enroll a total of 360 patients. GV1001 at doses of 0.56mg and 1.12mg will be administered subcutaneously, in a multicenter, randomized, double-blind, placebo-controlled, adaptive phase 2b/3 design. The trial will be conducted at domestic institutions including Seoul Boramae Hospital, with some sites yet to be confirmed.
Primary Endpoint: Change in PSPRS Total Score at 72 Weeks
The primary efficacy endpoint is the change from baseline in the Progressive Supranuclear Palsy Rating Scale (PSPRS) total score at 72 weeks. Through this, Samsung Pharm plans to select the optimal dose compared to placebo and confirm therapeutic efficacy. Therapeutic effects on cognitive function, decline in activities of daily living, and overall worsening of clinical symptoms, as well as safety during the treatment period, will also be evaluated.
Product License Application Upon Completion... Moving Toward Launch
The trial period is approximately 50 months from the date of approval by regulatory authorities and institutional review boards (IRBs), though it may be extended depending on patient enrollment speed.
After completing the trial, Samsung Pharm plans to apply for formal product approval for the progressive supranuclear palsy indication depending on the results. Once approval is obtained, the company intends to proceed with marketing and supply of the treatment.
Approval Odds Around 10%... Investment Cautions Specified
The company noted as an investment caution that the probability of the investigational drug ultimately receiving drug approval is statistically known to be around 10%. It stated that results during the clinical trial and product approval process may fall short of expectations, and that it may therefore modify or abandon its commercialization plans.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



